These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 23462434)

  • 21. Clinical immunotoxicity of antirheumatic drugs.
    Bálint G; Gergely P
    Inflamm Res; 1996 Dec; 45 Suppl 2():S91-5. PubMed ID: 8988409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Uveitis treated with biotherapy and/or DMARD: Analysis from the French Pharmacovigilance Study Base].
    Cabane L; Baillif S; Baldin B; Breuil V; Euller-Ziegler L; Tieulié N
    J Fr Ophtalmol; 2018 Apr; 41(4):350-356. PubMed ID: 29656829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neonatal outcomes of children born to mothers on biological agents during pregnancy: State of the art and perspectives.
    De Lorenzo R; Ramirez GA; Punzo D; Lorioli L; Rovelli R; Canti V; Barera G; Rovere-Querini P
    Pharmacol Res; 2020 Feb; 152():104583. PubMed ID: 31816434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thyroid-specific changes following treatment with biological therapies in patients with rheumatic diseases.
    Kaklamanos M; Thomas D; Pikazis D; Kaltsas G
    Endocrine; 2015 Sep; 50(1):146-53. PubMed ID: 25690756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of rheumatic diseases in children: special considerations.
    Milojevic DS; Ilowite NT
    Rheum Dis Clin North Am; 2002 Aug; 28(3):461-82. PubMed ID: 12380365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk.
    Khasnis AA; Calabrese LH
    Semin Arthritis Rheum; 2010 Oct; 40(2):147-63. PubMed ID: 19914686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A retrospective review of the adverse effects of biological therapy and reasons for its discontinuation in a resource-limited setting.
    Rood JW; Du Toit R
    S Afr Med J; 2020 Nov; 110(12):1231-1237. PubMed ID: 33403971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Malignancy and the Risks of Biologic Therapies: Current Status.
    Seror R; Mariette X
    Rheum Dis Clin North Am; 2017 Feb; 43(1):43-64. PubMed ID: 27890173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pediatric rheumatology for the adult rheumatologist.
    Wagner-Weiner L
    J Clin Rheumatol; 2008 Apr; 14(2):109-19. PubMed ID: 18391684
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploring the binding sites of anti-infliximab antibodies in pediatric patients with rheumatic diseases treated with infliximab.
    Kosmač M; Avčin T; Toplak N; Simonini G; Cimaz R; Curin Šerbec V
    Pediatr Res; 2011 Mar; 69(3):243-8. PubMed ID: 21131896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The perioperative use of biologic agents in patients with rheumatoid arthritis.
    Polachek A; Caspi D; Elkayam O
    Autoimmun Rev; 2012 Dec; 12(2):164-8. PubMed ID: 22522087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors associated with severe skin infections in patients treated with biologic therapies for inflammatory rheumatic diseases.
    Régnier-Rosencher E; Farhi D; Lebrun A; Salliot C; Dougados M; Dupin N
    Dermatology; 2012; 224(1):72-83. PubMed ID: 22487697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of coccidioidomycosis in patients receiving biologic response modifiers or disease-modifying antirheumatic drugs.
    Taroumian S; Knowles SL; Lisse JR; Yanes J; Ampel NM; Vaz A; Galgiani JN; Hoover SE
    Arthritis Care Res (Hoboken); 2012 Dec; 64(12):1903-9. PubMed ID: 22745051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Malignancy risks with biologic therapies.
    Cush JJ; Dao KH
    Rheum Dis Clin North Am; 2012 Nov; 38(4):761-70. PubMed ID: 23137581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rheumatic manifestations of hepatitis.
    Vassilopoulos D; Manolakopoulos S
    Curr Opin Rheumatol; 2010 Jan; 22(1):91-6. PubMed ID: 19864952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of biological agents and tissue engineering approaches on the treatment of rheumatic diseases.
    da Silva MA; Martins A; Teixeira AA; Reis RL; Neves NM
    Tissue Eng Part B Rev; 2010 Jun; 16(3):331-9. PubMed ID: 20025434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complications of Treatments for Pediatric Rheumatic Diseases.
    Higgins GC
    Pediatr Clin North Am; 2018 Aug; 65(4):827-854. PubMed ID: 30031500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigenetic Modulation as a Therapeutic Prospect for Treatment of Autoimmune Rheumatic Diseases.
    Ciechomska M; O'Reilly S
    Mediators Inflamm; 2016; 2016():9607946. PubMed ID: 27594771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pulmonary complications of childhood rheumatic disease.
    Rabinovich CE
    Paediatr Respir Rev; 2012 Mar; 13(1):29-36. PubMed ID: 22208791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Poorer functionality is related to better quality of life response following the use of biological drugs: 6-month outcomes in a prospective cohort from the Public Health System (Sistema Único de Saúde), Minas Gerais, Brazil.
    de Oliveira Junior HA; dos Santos JB; Acurcio FA; Almeida AM; Kakehasi AM; Alvares J; de Carvalho LF; Cherchiglia ML
    Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):403-12. PubMed ID: 25603696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.